- Latest analysis suggests that individuals should still drop a few pounds whereas staying on the bottom beginning doses of GLP-1 drugs, comparable to Wegovy or Zepbound, for longer durations.
- After one yr, individuals taking sustained low dose tirzepatide misplaced about 5.5% of their physique weight, whereas these taking sustained low dose semaglutide misplaced about 2.2%.
- Decrease doses have been related to extra modest weight reduction than greater doses, however sustained low dose semaglutide was additionally related to decrease charges of some unintended effects.
Individuals should still be capable of expertise weight reduction by staying on decrease beginning doses of GLP-1 drugs, comparable to Wegovy or Zepbound, for longer, in keeping with analysis printed in Biology Methods & Protocols on August 31.
Staying on decrease doses of GLP-1 drugs for longer could overlap with a apply generally known as “microdosing,” which has turn out to be a pattern amongst celebrities and on social media.
Nevertheless, the research didn’t set up that individuals have been deliberately microdosing, and utilizing these drugs outdoors their accepted dosing schedules will not be FDA- or manufacturer-approved.
The research included digital well being information from 814 people who met the factors for sustained low dose semaglutide (Ozempic, Wegovy), outlined as no less than three 0.25 mg doses spanning no less than six months. It additionally included 1,016 people who met the factors for sustained low dose tirzepatide (Mounjaro, Zepbound), outlined as 2.5 mg doses spanning no less than six months.
They discovered that these taking sustained low dose tirzepatide for one yr noticed round a 5.5% weight reduction, whereas these taking sustained low dose semaglutide for a similar interval noticed round a 2.2% weight reduction.
The researchers additionally in contrast weight reduction trajectories between these taking low dose and excessive dose semaglutide. After matching individuals based mostly on age, intercourse, BMI, and kind 2 diabetes standing, they discovered that these on low dose semaglutide skilled 1.7% weight reduction whereas these on excessive dose semaglutide had about 12% weight reduction.
“These findings introduce an vital remedy paradigm towards growing the notice round ‘microdosing’ for sufferers whose objective is cardiometabolic well being with lesser unintended effects than typical dose escalation of those medicines and an related modest sustained weight reduction within the 2-7% vary from baseline,” Venky Soundararajan, PhD, co-founder, chief scientific officer for nference, and co-author of the research, instructed Healthline.
Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Heart at Orange Coast Medical Heart in Fountain Valley, CA, who wasn’t concerned within the research, mentioned it isn’t shocking to see that individuals taking GLP-1 drugs can drop a few pounds even on the lowest dose.
“I’ve seen this in my very own apply. Though these starter doses are usually supposed to assist sufferers modify to the treatment, some individuals could expertise significant weight reduction even at these decrease doses,” he added.
Soundararajan famous that weight reductions remained evident by means of the 15-month follow-up. This implies that the initiation dose could probably function a sustained upkeep technique over many months, slightly than merely a quick stepping stone to a better dose, significantly for a affected person who has already achieved the load loss and cardiometabolic profit they’re in search of.
Nevertheless, Ali cautioned, “In my expertise, many sufferers ultimately attain some extent the place they cease reducing weight on the bottom dose, though particular person responses can range significantly. Some sufferers could obtain passable outcomes on a low dose, however most will want some extent of dose escalation to proceed reducing weight and attain their objectives.”
It is very important remember that whereas some individuals expertise fewer unintended effects, microdosing could not scale back the unintended effects of GLP-1 drugs for everybody.
- nausea or vomiting
- response on the injection web site
- diarrhea
- constipation
Soundararajan instructed Healthline that low dose tirzepatide (Zepbound, Mounjaro) was related to modestly extra weight reduction, whereas the general adverse-event sample (unintended effects) considerably favored low dose semaglutide (Wegovy), which can be significantly related for people prioritizing cardiometabolic well being and tolerability over maximal weight discount.
“In contrast with sufferers escalating to standard greater doses, sustained lowest-dose semaglutide was related to decrease 24-month charges of constipation (23.3% vs 36.3%), nausea (39.7% vs 50.1%), and low blood stress (1.7% vs 5.4%),” he mentioned.
“This implies that precision weight problems care could more and more contain asking not solely, ‘How a lot weight can this drug assist somebody lose?’ but additionally, ‘What’s the lowest dose that achieves this affected person’s cardiometabolic objectives with one of the best tolerability?’”
Ali additionally famous that these findings reinforce that GLP-1 drugs may be efficient for weight reduction even at their lowest doses.
“Nevertheless, the quantity of weight reduction at these doses tends to be extra modest than what’s seen with greater upkeep doses. For many individuals, steadily growing the dose could also be needed to attain better or continued weight reduction, however the applicable dose finally depends upon the person’s response, remedy objectives, and talent to tolerate the treatment,” he added.
